Paolo Cameli
Department of Medicine, Surgery and Neurosciences, Respiratory Diseases Unit · University of Siena
Research Interests
interstitial lung diseases biomarker server asthma rare lung diseases
Biography
Paolo Cameli completed his medical university training course at the universities of Siena and Florence and is currently actively involved in national (SIP, SANI) and international (ERS, ERN, WASOG) research groups. His main lines of research are focused on severe asthma and interstitial lung diseases, dealing specifically with the identification and validation in the clinical and biological field of markers of severity, prognosis and response to treatment. He had the merit of coordinating a research group involving various professional figures (doctors, biologists and biostatisticians), in order to contribute to the knowledge on the markers of exhaled breath, bronchoalveolar lavage and serum, analyzed through methods of molecular, cellular and - omics. These studies are mainly focused on rare lung diseases and on the different endotypes of severe asthma. He is author / co-author of over 120 publications in international journals with impact factor and peer-reviewed and participates as
Education
09/12/2021-ongoing Second level Master Course in Rare Diseases University of Firenze 02/10/2018-01/10/2021 PhD in Genetics, Oncology and Clinical Medicine (GENOMEC), XXXIV cycle. Thesis: “The impact of antifibrotic therapy in the management of idiopathic pulmonary fibrosis and progressive fibrosing interstitial lung diseases: a real-world comparative study of efficacy between pirfenidone and nintedanib” University of Siena 23/04/2021 National Scientific Qualification for the role of second-tier University Professor in the competition sector 06 / D1 - Cardiovascular System Diseases and Resp...
Recent Scopus Publications
- Longitudinal Multimodal Assessment of Pulmonary Nodules in Fibrosing Interstitial Lung Diseases: A Retrospective Study
- Clinical remission in patients with severe eosinophilic asthma treated with benralizumab over 24 months: Post hoc analysis of the ANANKE study
- Epidemiology of idiopathic pulmonary fibrosis: a population registry-based study
- Former smokers with severe eosinophilic asthma respond to benralizumab as effectively as never-smokers: a post hoc analysis of the ANANKE study
- Adding pieces to the puzzle: IL-33 contribution to fibrogenesis in chronic lung allograft dysfunction
Links
- ORCID https://orcid.org/0000-0001-8639-2882
- Google Scholar https://scholar.google.com/citations?user=3xToyVEAAAAJ
- Scopus https://www.scopus.com/authid/detail.uri?authorId=55490604400